Viewing nowCombinationPromet XR Extended-Release Tablet 100/1000 mg
Sitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Aju Pharmaceutical Co., Ltd.

MFDS item code 202201967 · Approved 2022.05.11 · Insurance code 654005910
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used to help manage blood sugar levels in patients with type 2 diabetes. It is particularly effective for those who are also engaging in dietary control and exercise therapy, as the two active ingredients, sitagliptin and metformin, work together to stabilize blood sugar. This helps improve blood sugar levels and aids in diabetes management.
The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medication should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. This medication 100/1000 mg extended-release tablet should be taken as 1 tablet once daily. Patients taking this medication 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug treatment who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medication is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. 2. Patients receiving metformin: - The recommended initial total daily dose of this medication for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 100 mg and their current dose of metformin. - Patients switching to this medication from concomitant sitagliptin and metformin therapy may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release metformin at a current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medication 50/1000 mg extended-release tablet once daily. 3. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medication is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin. Patients with renal impairment This medication may be used, with the following dosage adjustment, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication must be discontinued immediately.
This medication contains two active ingredients, sitagliptin and metformin, which are each used for treating diabetes. First, sitagliptin can rarely cause severe allergic reactions; if symptoms such as skin rash or difficulty breathing occur, discontinue use immediately. Acute pancreatitis may also occur, so if experiencing abdominal pain, vomiting, or severe dyspeptic symptoms, consult a doctor right away. Metformin can cause a rare but serious side effect known as lactic acidosis, which is characterized by excessive accumulation of lactic acid in the body, with symptoms including fatigue, muscle pain, difficulty breathing, and abdominal pain. If these symptoms arise, discontinue the medication and inform healthcare professionals immediately. This medication should not be administered to patients with moderate to severe renal impairment, severe infections, heart failure, or acute myocardial infarction. Additionally, women who are pregnant or breastfeeding, as well as patients with severely impaired liver function, should not take this medication. While taking this medication, regular monitoring of kidney function and blood tests is necessary, particularly for elderly patients or those with slightly reduced kidney function. During treatment, it is important to maintain a regular diet and appropriate exercise; irregular or inadequate food intake may increase the risk of hypoglycemia. If used in conjunction with other antihyperglycemic agents or insulin, increased vigilance is needed for hypoglycemic symptoms, and it is crucial to consume sugars immediately if symptoms occur. When undergoing surgery or tests that use contrast agents, temporarily discontinue this medication, and resume only after confirming normal kidney function post-examination. Alcohol consumption may increase the risk of lactic acidosis, so it is advisable to avoid drinking while on this medication. Lastly, safety and efficacy have not been established for children; therefore, patients under 18 years should not take this medication. If any unusual symptoms occur while taking this medication, it is important to consult healthcare professionals immediately to receive appropriate care.
Not everyone experiences these, and they can vary from person to person.
This medication can be sensitive to air and moisture; therefore, it should be stored in a tightly sealed container. It is recommended to maintain a storage temperature between 1 and 30 degrees Celsius. Proper storage will help preserve the medication's effectiveness for a longer duration.
Bright blue, double-convex oval-shaped extended-release film-coated tablet
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Aju Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.